Nuvation Bio Inc. has published a corporate presentation detailing its progress and current focus in oncology. The company, recognized as a global, commercial-stage entity, has recently achieved regulatory approval for IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor for advanced ROS1+ non-small cell lung cancer (NSCLC), in the U.S., Japan, and China. Additionally, Nuvation Bio is advancing its pipeline with Safusidenib, a brain-penetrant mIDH1 inhibitor, entering pivotal studies for diffuse IDH1-mutant glioma, and NUV-1511, a clinical-stage drug-drug conjugate undergoing Phase 1/2 evaluation. The company boasts a robust cash balance of $608 million as of June 30, 2025, ensuring a path to profitability without the need for additional funding. You can access the full presentation through the link below.